KUALA LUMPUR (Reuters) – Malaysia on Tuesday struck deals with two domestic companies to purchase 18.4 million doses of COVID-19 vaccines produced by Russia’s Gamaleya Institute and China’s Sinovac, the health ministry said.
Malaysian pharmaceutical firm Duopharma will supply the government with 6.4 million doses of Gamaleya’s Sputnik V vaccine, the ministry said in a statement. It said Malaysia Pharmaniaga Berhad will supply 12 million doses of Sinovac’s vaccine.
(Reporting by Rozanna Latiff and Joseph Sipalan; Editing by Martin Petty)
